Global Psychiatric Long-acting Injection Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Psychiatric Long-acting Injection market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Psychiatric Long-acting Injection Industry Forecast” looks at past sales and reviews total world Psychiatric Long-acting Injection sales in 2023, providing a comprehensive analysis by region and market sector of projected Psychiatric Long-acting Injection sales for 2024 through 2030. With Psychiatric Long-acting Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Psychiatric Long-acting Injection industry.
This Insight Report provides a comprehensive analysis of the global Psychiatric Long-acting Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Psychiatric Long-acting Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Psychiatric Long-acting Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Psychiatric Long-acting Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Psychiatric Long-acting Injection.
United States market for Psychiatric Long-acting Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Psychiatric Long-acting Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Psychiatric Long-acting Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Psychiatric Long-acting Injection players cover Oakwood Labs, Teva, MedinCell, Janssen, Otsuka America Pharmaceutical, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Psychiatric Long-acting Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Psychiatric Long-acting Injection market?
What factors are driving Psychiatric Long-acting Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Psychiatric Long-acting Injection market opportunities vary by end market size?
How does Psychiatric Long-acting Injection break out by Type, by Application?
The global Psychiatric Long-acting Injection market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Psychiatric Long-acting Injection Industry Forecast” looks at past sales and reviews total world Psychiatric Long-acting Injection sales in 2023, providing a comprehensive analysis by region and market sector of projected Psychiatric Long-acting Injection sales for 2024 through 2030. With Psychiatric Long-acting Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Psychiatric Long-acting Injection industry.
This Insight Report provides a comprehensive analysis of the global Psychiatric Long-acting Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Psychiatric Long-acting Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Psychiatric Long-acting Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Psychiatric Long-acting Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Psychiatric Long-acting Injection.
United States market for Psychiatric Long-acting Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Psychiatric Long-acting Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Psychiatric Long-acting Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Psychiatric Long-acting Injection players cover Oakwood Labs, Teva, MedinCell, Janssen, Otsuka America Pharmaceutical, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Psychiatric Long-acting Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Aripiprazole Long-acting Injection
- Haloperidol Long-acting Injection
- Paliperidone Long-acting Injection
- Risperidone Long-acting Injection
- Olanzapine Long-acting Injection
- Others
- Schizophrenia
- Bipolar Disorder
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Oakwood Labs
- Teva
- MedinCell
- Janssen
- Otsuka America Pharmaceutical, Inc.
- Lundbeck
- Eli Lilly
- Alkermes
- Par Pharmaceutical
- AbbVie
- Luye Pharmaceutical
What is the 10-year outlook for the global Psychiatric Long-acting Injection market?
What factors are driving Psychiatric Long-acting Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Psychiatric Long-acting Injection market opportunities vary by end market size?
How does Psychiatric Long-acting Injection break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Psychiatric Long-acting Injection Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Psychiatric Long-acting Injection by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Psychiatric Long-acting Injection by Country/Region, 2019, 2023 & 2030
2.2 Psychiatric Long-acting Injection Segment by Type
2.2.1 Aripiprazole Long-acting Injection
2.2.2 Haloperidol Long-acting Injection
2.2.3 Paliperidone Long-acting Injection
2.2.4 Risperidone Long-acting Injection
2.2.5 Olanzapine Long-acting Injection
2.2.6 Others
2.3 Psychiatric Long-acting Injection Sales by Type
2.3.1 Global Psychiatric Long-acting Injection Sales Market Share by Type (2019-2024)
2.3.2 Global Psychiatric Long-acting Injection Revenue and Market Share by Type (2019-2024)
2.3.3 Global Psychiatric Long-acting Injection Sale Price by Type (2019-2024)
2.4 Psychiatric Long-acting Injection Segment by Application
2.4.1 Schizophrenia
2.4.2 Bipolar Disorder
2.4.3 Others
2.5 Psychiatric Long-acting Injection Sales by Application
2.5.1 Global Psychiatric Long-acting Injection Sale Market Share by Application (2019-2024)
2.5.2 Global Psychiatric Long-acting Injection Revenue and Market Share by Application (2019-2024)
2.5.3 Global Psychiatric Long-acting Injection Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Psychiatric Long-acting Injection Breakdown Data by Company
3.1.1 Global Psychiatric Long-acting Injection Annual Sales by Company (2019-2024)
3.1.2 Global Psychiatric Long-acting Injection Sales Market Share by Company (2019-2024)
3.2 Global Psychiatric Long-acting Injection Annual Revenue by Company (2019-2024)
3.2.1 Global Psychiatric Long-acting Injection Revenue by Company (2019-2024)
3.2.2 Global Psychiatric Long-acting Injection Revenue Market Share by Company (2019-2024)
3.3 Global Psychiatric Long-acting Injection Sale Price by Company
3.4 Key Manufacturers Psychiatric Long-acting Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Psychiatric Long-acting Injection Product Location Distribution
3.4.2 Players Psychiatric Long-acting Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PSYCHIATRIC LONG-ACTING INJECTION BY GEOGRAPHIC REGION
4.1 World Historic Psychiatric Long-acting Injection Market Size by Geographic Region (2019-2024)
4.1.1 Global Psychiatric Long-acting Injection Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Psychiatric Long-acting Injection Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Psychiatric Long-acting Injection Market Size by Country/Region (2019-2024)
4.2.1 Global Psychiatric Long-acting Injection Annual Sales by Country/Region (2019-2024)
4.2.2 Global Psychiatric Long-acting Injection Annual Revenue by Country/Region (2019-2024)
4.3 Americas Psychiatric Long-acting Injection Sales Growth
4.4 APAC Psychiatric Long-acting Injection Sales Growth
4.5 Europe Psychiatric Long-acting Injection Sales Growth
4.6 Middle East & Africa Psychiatric Long-acting Injection Sales Growth
5 AMERICAS
5.1 Americas Psychiatric Long-acting Injection Sales by Country
5.1.1 Americas Psychiatric Long-acting Injection Sales by Country (2019-2024)
5.1.2 Americas Psychiatric Long-acting Injection Revenue by Country (2019-2024)
5.2 Americas Psychiatric Long-acting Injection Sales by Type (2019-2024)
5.3 Americas Psychiatric Long-acting Injection Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Psychiatric Long-acting Injection Sales by Region
6.1.1 APAC Psychiatric Long-acting Injection Sales by Region (2019-2024)
6.1.2 APAC Psychiatric Long-acting Injection Revenue by Region (2019-2024)
6.2 APAC Psychiatric Long-acting Injection Sales by Type (2019-2024)
6.3 APAC Psychiatric Long-acting Injection Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Psychiatric Long-acting Injection by Country
7.1.1 Europe Psychiatric Long-acting Injection Sales by Country (2019-2024)
7.1.2 Europe Psychiatric Long-acting Injection Revenue by Country (2019-2024)
7.2 Europe Psychiatric Long-acting Injection Sales by Type (2019-2024)
7.3 Europe Psychiatric Long-acting Injection Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Psychiatric Long-acting Injection by Country
8.1.1 Middle East & Africa Psychiatric Long-acting Injection Sales by Country (2019-2024)
8.1.2 Middle East & Africa Psychiatric Long-acting Injection Revenue by Country (2019-2024)
8.2 Middle East & Africa Psychiatric Long-acting Injection Sales by Type (2019-2024)
8.3 Middle East & Africa Psychiatric Long-acting Injection Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Psychiatric Long-acting Injection
10.3 Manufacturing Process Analysis of Psychiatric Long-acting Injection
10.4 Industry Chain Structure of Psychiatric Long-acting Injection
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Psychiatric Long-acting Injection Distributors
11.3 Psychiatric Long-acting Injection Customer
12 WORLD FORECAST REVIEW FOR PSYCHIATRIC LONG-ACTING INJECTION BY GEOGRAPHIC REGION
12.1 Global Psychiatric Long-acting Injection Market Size Forecast by Region
12.1.1 Global Psychiatric Long-acting Injection Forecast by Region (2025-2030)
12.1.2 Global Psychiatric Long-acting Injection Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Psychiatric Long-acting Injection Forecast by Type (2025-2030)
12.7 Global Psychiatric Long-acting Injection Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Oakwood Labs
13.1.1 Oakwood Labs Company Information
13.1.2 Oakwood Labs Psychiatric Long-acting Injection Product Portfolios and Specifications
13.1.3 Oakwood Labs Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Oakwood Labs Main Business Overview
13.1.5 Oakwood Labs Latest Developments
13.2 Teva
13.2.1 Teva Company Information
13.2.2 Teva Psychiatric Long-acting Injection Product Portfolios and Specifications
13.2.3 Teva Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Teva Main Business Overview
13.2.5 Teva Latest Developments
13.3 MedinCell
13.3.1 MedinCell Company Information
13.3.2 MedinCell Psychiatric Long-acting Injection Product Portfolios and Specifications
13.3.3 MedinCell Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 MedinCell Main Business Overview
13.3.5 MedinCell Latest Developments
13.4 Janssen
13.4.1 Janssen Company Information
13.4.2 Janssen Psychiatric Long-acting Injection Product Portfolios and Specifications
13.4.3 Janssen Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Janssen Main Business Overview
13.4.5 Janssen Latest Developments
13.5 Otsuka America Pharmaceutical, Inc.
13.5.1 Otsuka America Pharmaceutical, Inc. Company Information
13.5.2 Otsuka America Pharmaceutical, Inc. Psychiatric Long-acting Injection Product Portfolios and Specifications
13.5.3 Otsuka America Pharmaceutical, Inc. Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Otsuka America Pharmaceutical, Inc. Main Business Overview
13.5.5 Otsuka America Pharmaceutical, Inc. Latest Developments
13.6 Lundbeck
13.6.1 Lundbeck Company Information
13.6.2 Lundbeck Psychiatric Long-acting Injection Product Portfolios and Specifications
13.6.3 Lundbeck Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Lundbeck Main Business Overview
13.6.5 Lundbeck Latest Developments
13.7 Eli Lilly
13.7.1 Eli Lilly Company Information
13.7.2 Eli Lilly Psychiatric Long-acting Injection Product Portfolios and Specifications
13.7.3 Eli Lilly Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Eli Lilly Main Business Overview
13.7.5 Eli Lilly Latest Developments
13.8 Alkermes
13.8.1 Alkermes Company Information
13.8.2 Alkermes Psychiatric Long-acting Injection Product Portfolios and Specifications
13.8.3 Alkermes Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Alkermes Main Business Overview
13.8.5 Alkermes Latest Developments
13.9 Par Pharmaceutical
13.9.1 Par Pharmaceutical Company Information
13.9.2 Par Pharmaceutical Psychiatric Long-acting Injection Product Portfolios and Specifications
13.9.3 Par Pharmaceutical Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Par Pharmaceutical Main Business Overview
13.9.5 Par Pharmaceutical Latest Developments
13.10 AbbVie
13.10.1 AbbVie Company Information
13.10.2 AbbVie Psychiatric Long-acting Injection Product Portfolios and Specifications
13.10.3 AbbVie Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 AbbVie Main Business Overview
13.10.5 AbbVie Latest Developments
13.11 Luye Pharmaceutical
13.11.1 Luye Pharmaceutical Company Information
13.11.2 Luye Pharmaceutical Psychiatric Long-acting Injection Product Portfolios and Specifications
13.11.3 Luye Pharmaceutical Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Luye Pharmaceutical Main Business Overview
13.11.5 Luye Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Psychiatric Long-acting Injection Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Psychiatric Long-acting Injection by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Psychiatric Long-acting Injection by Country/Region, 2019, 2023 & 2030
2.2 Psychiatric Long-acting Injection Segment by Type
2.2.1 Aripiprazole Long-acting Injection
2.2.2 Haloperidol Long-acting Injection
2.2.3 Paliperidone Long-acting Injection
2.2.4 Risperidone Long-acting Injection
2.2.5 Olanzapine Long-acting Injection
2.2.6 Others
2.3 Psychiatric Long-acting Injection Sales by Type
2.3.1 Global Psychiatric Long-acting Injection Sales Market Share by Type (2019-2024)
2.3.2 Global Psychiatric Long-acting Injection Revenue and Market Share by Type (2019-2024)
2.3.3 Global Psychiatric Long-acting Injection Sale Price by Type (2019-2024)
2.4 Psychiatric Long-acting Injection Segment by Application
2.4.1 Schizophrenia
2.4.2 Bipolar Disorder
2.4.3 Others
2.5 Psychiatric Long-acting Injection Sales by Application
2.5.1 Global Psychiatric Long-acting Injection Sale Market Share by Application (2019-2024)
2.5.2 Global Psychiatric Long-acting Injection Revenue and Market Share by Application (2019-2024)
2.5.3 Global Psychiatric Long-acting Injection Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Psychiatric Long-acting Injection Breakdown Data by Company
3.1.1 Global Psychiatric Long-acting Injection Annual Sales by Company (2019-2024)
3.1.2 Global Psychiatric Long-acting Injection Sales Market Share by Company (2019-2024)
3.2 Global Psychiatric Long-acting Injection Annual Revenue by Company (2019-2024)
3.2.1 Global Psychiatric Long-acting Injection Revenue by Company (2019-2024)
3.2.2 Global Psychiatric Long-acting Injection Revenue Market Share by Company (2019-2024)
3.3 Global Psychiatric Long-acting Injection Sale Price by Company
3.4 Key Manufacturers Psychiatric Long-acting Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Psychiatric Long-acting Injection Product Location Distribution
3.4.2 Players Psychiatric Long-acting Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PSYCHIATRIC LONG-ACTING INJECTION BY GEOGRAPHIC REGION
4.1 World Historic Psychiatric Long-acting Injection Market Size by Geographic Region (2019-2024)
4.1.1 Global Psychiatric Long-acting Injection Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Psychiatric Long-acting Injection Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Psychiatric Long-acting Injection Market Size by Country/Region (2019-2024)
4.2.1 Global Psychiatric Long-acting Injection Annual Sales by Country/Region (2019-2024)
4.2.2 Global Psychiatric Long-acting Injection Annual Revenue by Country/Region (2019-2024)
4.3 Americas Psychiatric Long-acting Injection Sales Growth
4.4 APAC Psychiatric Long-acting Injection Sales Growth
4.5 Europe Psychiatric Long-acting Injection Sales Growth
4.6 Middle East & Africa Psychiatric Long-acting Injection Sales Growth
5 AMERICAS
5.1 Americas Psychiatric Long-acting Injection Sales by Country
5.1.1 Americas Psychiatric Long-acting Injection Sales by Country (2019-2024)
5.1.2 Americas Psychiatric Long-acting Injection Revenue by Country (2019-2024)
5.2 Americas Psychiatric Long-acting Injection Sales by Type (2019-2024)
5.3 Americas Psychiatric Long-acting Injection Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Psychiatric Long-acting Injection Sales by Region
6.1.1 APAC Psychiatric Long-acting Injection Sales by Region (2019-2024)
6.1.2 APAC Psychiatric Long-acting Injection Revenue by Region (2019-2024)
6.2 APAC Psychiatric Long-acting Injection Sales by Type (2019-2024)
6.3 APAC Psychiatric Long-acting Injection Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Psychiatric Long-acting Injection by Country
7.1.1 Europe Psychiatric Long-acting Injection Sales by Country (2019-2024)
7.1.2 Europe Psychiatric Long-acting Injection Revenue by Country (2019-2024)
7.2 Europe Psychiatric Long-acting Injection Sales by Type (2019-2024)
7.3 Europe Psychiatric Long-acting Injection Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Psychiatric Long-acting Injection by Country
8.1.1 Middle East & Africa Psychiatric Long-acting Injection Sales by Country (2019-2024)
8.1.2 Middle East & Africa Psychiatric Long-acting Injection Revenue by Country (2019-2024)
8.2 Middle East & Africa Psychiatric Long-acting Injection Sales by Type (2019-2024)
8.3 Middle East & Africa Psychiatric Long-acting Injection Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Psychiatric Long-acting Injection
10.3 Manufacturing Process Analysis of Psychiatric Long-acting Injection
10.4 Industry Chain Structure of Psychiatric Long-acting Injection
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Psychiatric Long-acting Injection Distributors
11.3 Psychiatric Long-acting Injection Customer
12 WORLD FORECAST REVIEW FOR PSYCHIATRIC LONG-ACTING INJECTION BY GEOGRAPHIC REGION
12.1 Global Psychiatric Long-acting Injection Market Size Forecast by Region
12.1.1 Global Psychiatric Long-acting Injection Forecast by Region (2025-2030)
12.1.2 Global Psychiatric Long-acting Injection Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Psychiatric Long-acting Injection Forecast by Type (2025-2030)
12.7 Global Psychiatric Long-acting Injection Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Oakwood Labs
13.1.1 Oakwood Labs Company Information
13.1.2 Oakwood Labs Psychiatric Long-acting Injection Product Portfolios and Specifications
13.1.3 Oakwood Labs Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Oakwood Labs Main Business Overview
13.1.5 Oakwood Labs Latest Developments
13.2 Teva
13.2.1 Teva Company Information
13.2.2 Teva Psychiatric Long-acting Injection Product Portfolios and Specifications
13.2.3 Teva Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Teva Main Business Overview
13.2.5 Teva Latest Developments
13.3 MedinCell
13.3.1 MedinCell Company Information
13.3.2 MedinCell Psychiatric Long-acting Injection Product Portfolios and Specifications
13.3.3 MedinCell Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 MedinCell Main Business Overview
13.3.5 MedinCell Latest Developments
13.4 Janssen
13.4.1 Janssen Company Information
13.4.2 Janssen Psychiatric Long-acting Injection Product Portfolios and Specifications
13.4.3 Janssen Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Janssen Main Business Overview
13.4.5 Janssen Latest Developments
13.5 Otsuka America Pharmaceutical, Inc.
13.5.1 Otsuka America Pharmaceutical, Inc. Company Information
13.5.2 Otsuka America Pharmaceutical, Inc. Psychiatric Long-acting Injection Product Portfolios and Specifications
13.5.3 Otsuka America Pharmaceutical, Inc. Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Otsuka America Pharmaceutical, Inc. Main Business Overview
13.5.5 Otsuka America Pharmaceutical, Inc. Latest Developments
13.6 Lundbeck
13.6.1 Lundbeck Company Information
13.6.2 Lundbeck Psychiatric Long-acting Injection Product Portfolios and Specifications
13.6.3 Lundbeck Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Lundbeck Main Business Overview
13.6.5 Lundbeck Latest Developments
13.7 Eli Lilly
13.7.1 Eli Lilly Company Information
13.7.2 Eli Lilly Psychiatric Long-acting Injection Product Portfolios and Specifications
13.7.3 Eli Lilly Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Eli Lilly Main Business Overview
13.7.5 Eli Lilly Latest Developments
13.8 Alkermes
13.8.1 Alkermes Company Information
13.8.2 Alkermes Psychiatric Long-acting Injection Product Portfolios and Specifications
13.8.3 Alkermes Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Alkermes Main Business Overview
13.8.5 Alkermes Latest Developments
13.9 Par Pharmaceutical
13.9.1 Par Pharmaceutical Company Information
13.9.2 Par Pharmaceutical Psychiatric Long-acting Injection Product Portfolios and Specifications
13.9.3 Par Pharmaceutical Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Par Pharmaceutical Main Business Overview
13.9.5 Par Pharmaceutical Latest Developments
13.10 AbbVie
13.10.1 AbbVie Company Information
13.10.2 AbbVie Psychiatric Long-acting Injection Product Portfolios and Specifications
13.10.3 AbbVie Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 AbbVie Main Business Overview
13.10.5 AbbVie Latest Developments
13.11 Luye Pharmaceutical
13.11.1 Luye Pharmaceutical Company Information
13.11.2 Luye Pharmaceutical Psychiatric Long-acting Injection Product Portfolios and Specifications
13.11.3 Luye Pharmaceutical Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Luye Pharmaceutical Main Business Overview
13.11.5 Luye Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Psychiatric Long-acting Injection Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Psychiatric Long-acting Injection Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Aripiprazole Long-acting Injection
Table 4. Major Players of Haloperidol Long-acting Injection
Table 5. Major Players of Paliperidone Long-acting Injection
Table 6. Major Players of Risperidone Long-acting Injection
Table 7. Major Players of Olanzapine Long-acting Injection
Table 8. Major Players of Others
Table 9. Global Psychiatric Long-acting Injection Sales by Type (2019-2024) & (K Units)
Table 10. Global Psychiatric Long-acting Injection Sales Market Share by Type (2019-2024)
Table 11. Global Psychiatric Long-acting Injection Revenue by Type (2019-2024) & ($ million)
Table 12. Global Psychiatric Long-acting Injection Revenue Market Share by Type (2019-2024)
Table 13. Global Psychiatric Long-acting Injection Sale Price by Type (2019-2024) & (US$/Unit)
Table 14. Global Psychiatric Long-acting Injection Sale by Application (2019-2024) & (K Units)
Table 15. Global Psychiatric Long-acting Injection Sale Market Share by Application (2019-2024)
Table 16. Global Psychiatric Long-acting Injection Revenue by Application (2019-2024) & ($ million)
Table 17. Global Psychiatric Long-acting Injection Revenue Market Share by Application (2019-2024)
Table 18. Global Psychiatric Long-acting Injection Sale Price by Application (2019-2024) & (US$/Unit)
Table 19. Global Psychiatric Long-acting Injection Sales by Company (2019-2024) & (K Units)
Table 20. Global Psychiatric Long-acting Injection Sales Market Share by Company (2019-2024)
Table 21. Global Psychiatric Long-acting Injection Revenue by Company (2019-2024) & ($ millions)
Table 22. Global Psychiatric Long-acting Injection Revenue Market Share by Company (2019-2024)
Table 23. Global Psychiatric Long-acting Injection Sale Price by Company (2019-2024) & (US$/Unit)
Table 24. Key Manufacturers Psychiatric Long-acting Injection Producing Area Distribution and Sales Area
Table 25. Players Psychiatric Long-acting Injection Products Offered
Table 26. Psychiatric Long-acting Injection Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global Psychiatric Long-acting Injection Sales by Geographic Region (2019-2024) & (K Units)
Table 30. Global Psychiatric Long-acting Injection Sales Market Share Geographic Region (2019-2024)
Table 31. Global Psychiatric Long-acting Injection Revenue by Geographic Region (2019-2024) & ($ millions)
Table 32. Global Psychiatric Long-acting Injection Revenue Market Share by Geographic Region (2019-2024)
Table 33. Global Psychiatric Long-acting Injection Sales by Country/Region (2019-2024) & (K Units)
Table 34. Global Psychiatric Long-acting Injection Sales Market Share by Country/Region (2019-2024)
Table 35. Global Psychiatric Long-acting Injection Revenue by Country/Region (2019-2024) & ($ millions)
Table 36. Global Psychiatric Long-acting Injection Revenue Market Share by Country/Region (2019-2024)
Table 37. Americas Psychiatric Long-acting Injection Sales by Country (2019-2024) & (K Units)
Table 38. Americas Psychiatric Long-acting Injection Sales Market Share by Country (2019-2024)
Table 39. Americas Psychiatric Long-acting Injection Revenue by Country (2019-2024) & ($ millions)
Table 40. Americas Psychiatric Long-acting Injection Sales by Type (2019-2024) & (K Units)
Table 41. Americas Psychiatric Long-acting Injection Sales by Application (2019-2024) & (K Units)
Table 42. APAC Psychiatric Long-acting Injection Sales by Region (2019-2024) & (K Units)
Table 43. APAC Psychiatric Long-acting Injection Sales Market Share by Region (2019-2024)
Table 44. APAC Psychiatric Long-acting Injection Revenue by Region (2019-2024) & ($ millions)
Table 45. APAC Psychiatric Long-acting Injection Sales by Type (2019-2024) & (K Units)
Table 46. APAC Psychiatric Long-acting Injection Sales by Application (2019-2024) & (K Units)
Table 47. Europe Psychiatric Long-acting Injection Sales by Country (2019-2024) & (K Units)
Table 48. Europe Psychiatric Long-acting Injection Revenue by Country (2019-2024) & ($ millions)
Table 49. Europe Psychiatric Long-acting Injection Sales by Type (2019-2024) & (K Units)
Table 50. Europe Psychiatric Long-acting Injection Sales by Application (2019-2024) & (K Units)
Table 51. Middle East & Africa Psychiatric Long-acting Injection Sales by Country (2019-2024) & (K Units)
Table 52. Middle East & Africa Psychiatric Long-acting Injection Revenue Market Share by Country (2019-2024)
Table 53. Middle East & Africa Psychiatric Long-acting Injection Sales by Type (2019-2024) & (K Units)
Table 54. Middle East & Africa Psychiatric Long-acting Injection Sales by Application (2019-2024) & (K Units)
Table 55. Key Market Drivers & Growth Opportunities of Psychiatric Long-acting Injection
Table 56. Key Market Challenges & Risks of Psychiatric Long-acting Injection
Table 57. Key Industry Trends of Psychiatric Long-acting Injection
Table 58. Psychiatric Long-acting Injection Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. Psychiatric Long-acting Injection Distributors List
Table 61. Psychiatric Long-acting Injection Customer List
Table 62. Global Psychiatric Long-acting Injection Sales Forecast by Region (2025-2030) & (K Units)
Table 63. Global Psychiatric Long-acting Injection Revenue Forecast by Region (2025-2030) & ($ millions)
Table 64. Americas Psychiatric Long-acting Injection Sales Forecast by Country (2025-2030) & (K Units)
Table 65. Americas Psychiatric Long-acting Injection Annual Revenue Forecast by Country (2025-2030) & ($ millions)
Table 66. APAC Psychiatric Long-acting Injection Sales Forecast by Region (2025-2030) & (K Units)
Table 67. APAC Psychiatric Long-acting Injection Annual Revenue Forecast by Region (2025-2030) & ($ millions)
Table 68. Europe Psychiatric Long-acting Injection Sales Forecast by Country (2025-2030) & (K Units)
Table 69. Europe Psychiatric Long-acting Injection Revenue Forecast by Country (2025-2030) & ($ millions)
Table 70. Middle East & Africa Psychiatric Long-acting Injection Sales Forecast by Country (2025-2030) & (K Units)
Table 71. Middle East & Africa Psychiatric Long-acting Injection Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. Global Psychiatric Long-acting Injection Sales Forecast by Type (2025-2030) & (K Units)
Table 73. Global Psychiatric Long-acting Injection Revenue Forecast by Type (2025-2030) & ($ millions)
Table 74. Global Psychiatric Long-acting Injection Sales Forecast by Application (2025-2030) & (K Units)
Table 75. Global Psychiatric Long-acting Injection Revenue Forecast by Application (2025-2030) & ($ millions)
Table 76. Oakwood Labs Basic Information, Psychiatric Long-acting Injection Manufacturing Base, Sales Area and Its Competitors
Table 77. Oakwood Labs Psychiatric Long-acting Injection Product Portfolios and Specifications
Table 78. Oakwood Labs Psychiatric Long-acting Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 79. Oakwood Labs Main Business
Table 80. Oakwood Labs Latest Developments
Table 81. Teva Basic Information, Psychiatric Long-acting Injection Manufacturing Base, Sales Area and Its Competitors
Table 82. Teva Psychiatric Long-acting Injection Product Portfolios and Specifications
Table 83. Teva Psychiatric Long-acting Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 84. Teva Main Business
Table 85. Teva Latest Developments
Table 86. MedinCell Basic Information, Psychiatric Long-acting Injection Manufacturing Base, Sales Area and Its Competitors
Table 87. MedinCell Psychiatric Long-acting Injection Product Portfolios and Specifications
Table 88. MedinCell Psychiatric Long-acting Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 89. MedinCell Main Business
Table 90. MedinCell Latest Developments
Table 91. Janssen Basic Information, Psychiatric Long-acting Injection Manufacturing Base, Sales Area and Its Competitors
Table 92. Janssen Psychiatric Long-acting Injection Product Portfolios and Specifications
Table 93. Janssen Psychiatric Long-acting Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 94. Janssen Main Business
Table 95. Janssen Latest Developments
Table 96. Otsuka America Pharmaceutical, Inc. Basic Information, Psychiatric Long-acting Injection Manufacturing Base, Sales Area and Its Competitors
Table 97. Otsuka America Pharmaceutical, Inc. Psychiatric Long-acting Injection Product Portfolios and Specifications
Table 98. Otsuka America Pharmaceutical, Inc. Psychiatric Long-acting Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 99. Otsuka America Pharmaceutical, Inc. Main Business
Table 100. Otsuka America Pharmaceutical, Inc. Latest Developments
Table 101. Lundbeck Basic Information, Psychiatric Long-acting Injection Manufacturing Base, Sales Area and Its Competitors
Table 102. Lundbeck Psychiatric Long-acting Injection Product Portfolios and Specifications
Table 103. Lundbeck Psychiatric Long-acting Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 104. Lundbeck Main Business
Table 105. Lundbeck Latest Developments
Table 106. Eli Lilly Basic Information, Psychiatric Long-acting Injection Manufacturing Base, Sales Area and Its Competitors
Table 107. Eli Lilly Psychiatric Long-acting Injection Product Portfolios and Specifications
Table 108. Eli Lilly Psychiatric Long-acting Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 109. Eli Lilly Main Business
Table 110. Eli Lilly Latest Developments
Table 111. Alkermes Basic Information, Psychiatric Long-acting Injection Manufacturing Base, Sales Area and Its Competitors
Table 112. Alkermes Psychiatric Long-acting Injection Product Portfolios and Specifications
Table 113. Alkermes Psychiatric Long-acting Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 114. Alkermes Main Business
Table 115. Alkermes Latest Developments
Table 116. Par Pharmaceutical Basic Information, Psychiatric Long-acting Injection Manufacturing Base, Sales Area and Its Competitors
Table 117. Par Pharmaceutical Psychiatric Long-acting Injection Product Portfolios and Specifications
Table 118. Par Pharmaceutical Psychiatric Long-acting Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 119. Par Pharmaceutical Main Business
Table 120. Par Pharmaceutical Latest Developments
Table 121. AbbVie Basic Information, Psychiatric Long-acting Injection Manufacturing Base, Sales Area and Its Competitors
Table 122. AbbVie Psychiatric Long-acting Injection Product Portfolios and Specifications
Table 123. AbbVie Psychiatric Long-acting Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 124. AbbVie Main Business
Table 125. AbbVie Latest Developments
Table 126. Luye Pharmaceutical Basic Information, Psychiatric Long-acting Injection Manufacturing Base, Sales Area and Its Competitors
Table 127. Luye Pharmaceutical Psychiatric Long-acting Injection Product Portfolios and Specifications
Table 128. Luye Pharmaceutical Psychiatric Long-acting Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 129. Luye Pharmaceutical Main Business
Table 130. Luye Pharmaceutical Latest Developments
Table 1. Psychiatric Long-acting Injection Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Psychiatric Long-acting Injection Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Aripiprazole Long-acting Injection
Table 4. Major Players of Haloperidol Long-acting Injection
Table 5. Major Players of Paliperidone Long-acting Injection
Table 6. Major Players of Risperidone Long-acting Injection
Table 7. Major Players of Olanzapine Long-acting Injection
Table 8. Major Players of Others
Table 9. Global Psychiatric Long-acting Injection Sales by Type (2019-2024) & (K Units)
Table 10. Global Psychiatric Long-acting Injection Sales Market Share by Type (2019-2024)
Table 11. Global Psychiatric Long-acting Injection Revenue by Type (2019-2024) & ($ million)
Table 12. Global Psychiatric Long-acting Injection Revenue Market Share by Type (2019-2024)
Table 13. Global Psychiatric Long-acting Injection Sale Price by Type (2019-2024) & (US$/Unit)
Table 14. Global Psychiatric Long-acting Injection Sale by Application (2019-2024) & (K Units)
Table 15. Global Psychiatric Long-acting Injection Sale Market Share by Application (2019-2024)
Table 16. Global Psychiatric Long-acting Injection Revenue by Application (2019-2024) & ($ million)
Table 17. Global Psychiatric Long-acting Injection Revenue Market Share by Application (2019-2024)
Table 18. Global Psychiatric Long-acting Injection Sale Price by Application (2019-2024) & (US$/Unit)
Table 19. Global Psychiatric Long-acting Injection Sales by Company (2019-2024) & (K Units)
Table 20. Global Psychiatric Long-acting Injection Sales Market Share by Company (2019-2024)
Table 21. Global Psychiatric Long-acting Injection Revenue by Company (2019-2024) & ($ millions)
Table 22. Global Psychiatric Long-acting Injection Revenue Market Share by Company (2019-2024)
Table 23. Global Psychiatric Long-acting Injection Sale Price by Company (2019-2024) & (US$/Unit)
Table 24. Key Manufacturers Psychiatric Long-acting Injection Producing Area Distribution and Sales Area
Table 25. Players Psychiatric Long-acting Injection Products Offered
Table 26. Psychiatric Long-acting Injection Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global Psychiatric Long-acting Injection Sales by Geographic Region (2019-2024) & (K Units)
Table 30. Global Psychiatric Long-acting Injection Sales Market Share Geographic Region (2019-2024)
Table 31. Global Psychiatric Long-acting Injection Revenue by Geographic Region (2019-2024) & ($ millions)
Table 32. Global Psychiatric Long-acting Injection Revenue Market Share by Geographic Region (2019-2024)
Table 33. Global Psychiatric Long-acting Injection Sales by Country/Region (2019-2024) & (K Units)
Table 34. Global Psychiatric Long-acting Injection Sales Market Share by Country/Region (2019-2024)
Table 35. Global Psychiatric Long-acting Injection Revenue by Country/Region (2019-2024) & ($ millions)
Table 36. Global Psychiatric Long-acting Injection Revenue Market Share by Country/Region (2019-2024)
Table 37. Americas Psychiatric Long-acting Injection Sales by Country (2019-2024) & (K Units)
Table 38. Americas Psychiatric Long-acting Injection Sales Market Share by Country (2019-2024)
Table 39. Americas Psychiatric Long-acting Injection Revenue by Country (2019-2024) & ($ millions)
Table 40. Americas Psychiatric Long-acting Injection Sales by Type (2019-2024) & (K Units)
Table 41. Americas Psychiatric Long-acting Injection Sales by Application (2019-2024) & (K Units)
Table 42. APAC Psychiatric Long-acting Injection Sales by Region (2019-2024) & (K Units)
Table 43. APAC Psychiatric Long-acting Injection Sales Market Share by Region (2019-2024)
Table 44. APAC Psychiatric Long-acting Injection Revenue by Region (2019-2024) & ($ millions)
Table 45. APAC Psychiatric Long-acting Injection Sales by Type (2019-2024) & (K Units)
Table 46. APAC Psychiatric Long-acting Injection Sales by Application (2019-2024) & (K Units)
Table 47. Europe Psychiatric Long-acting Injection Sales by Country (2019-2024) & (K Units)
Table 48. Europe Psychiatric Long-acting Injection Revenue by Country (2019-2024) & ($ millions)
Table 49. Europe Psychiatric Long-acting Injection Sales by Type (2019-2024) & (K Units)
Table 50. Europe Psychiatric Long-acting Injection Sales by Application (2019-2024) & (K Units)
Table 51. Middle East & Africa Psychiatric Long-acting Injection Sales by Country (2019-2024) & (K Units)
Table 52. Middle East & Africa Psychiatric Long-acting Injection Revenue Market Share by Country (2019-2024)
Table 53. Middle East & Africa Psychiatric Long-acting Injection Sales by Type (2019-2024) & (K Units)
Table 54. Middle East & Africa Psychiatric Long-acting Injection Sales by Application (2019-2024) & (K Units)
Table 55. Key Market Drivers & Growth Opportunities of Psychiatric Long-acting Injection
Table 56. Key Market Challenges & Risks of Psychiatric Long-acting Injection
Table 57. Key Industry Trends of Psychiatric Long-acting Injection
Table 58. Psychiatric Long-acting Injection Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. Psychiatric Long-acting Injection Distributors List
Table 61. Psychiatric Long-acting Injection Customer List
Table 62. Global Psychiatric Long-acting Injection Sales Forecast by Region (2025-2030) & (K Units)
Table 63. Global Psychiatric Long-acting Injection Revenue Forecast by Region (2025-2030) & ($ millions)
Table 64. Americas Psychiatric Long-acting Injection Sales Forecast by Country (2025-2030) & (K Units)
Table 65. Americas Psychiatric Long-acting Injection Annual Revenue Forecast by Country (2025-2030) & ($ millions)
Table 66. APAC Psychiatric Long-acting Injection Sales Forecast by Region (2025-2030) & (K Units)
Table 67. APAC Psychiatric Long-acting Injection Annual Revenue Forecast by Region (2025-2030) & ($ millions)
Table 68. Europe Psychiatric Long-acting Injection Sales Forecast by Country (2025-2030) & (K Units)
Table 69. Europe Psychiatric Long-acting Injection Revenue Forecast by Country (2025-2030) & ($ millions)
Table 70. Middle East & Africa Psychiatric Long-acting Injection Sales Forecast by Country (2025-2030) & (K Units)
Table 71. Middle East & Africa Psychiatric Long-acting Injection Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. Global Psychiatric Long-acting Injection Sales Forecast by Type (2025-2030) & (K Units)
Table 73. Global Psychiatric Long-acting Injection Revenue Forecast by Type (2025-2030) & ($ millions)
Table 74. Global Psychiatric Long-acting Injection Sales Forecast by Application (2025-2030) & (K Units)
Table 75. Global Psychiatric Long-acting Injection Revenue Forecast by Application (2025-2030) & ($ millions)
Table 76. Oakwood Labs Basic Information, Psychiatric Long-acting Injection Manufacturing Base, Sales Area and Its Competitors
Table 77. Oakwood Labs Psychiatric Long-acting Injection Product Portfolios and Specifications
Table 78. Oakwood Labs Psychiatric Long-acting Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 79. Oakwood Labs Main Business
Table 80. Oakwood Labs Latest Developments
Table 81. Teva Basic Information, Psychiatric Long-acting Injection Manufacturing Base, Sales Area and Its Competitors
Table 82. Teva Psychiatric Long-acting Injection Product Portfolios and Specifications
Table 83. Teva Psychiatric Long-acting Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 84. Teva Main Business
Table 85. Teva Latest Developments
Table 86. MedinCell Basic Information, Psychiatric Long-acting Injection Manufacturing Base, Sales Area and Its Competitors
Table 87. MedinCell Psychiatric Long-acting Injection Product Portfolios and Specifications
Table 88. MedinCell Psychiatric Long-acting Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 89. MedinCell Main Business
Table 90. MedinCell Latest Developments
Table 91. Janssen Basic Information, Psychiatric Long-acting Injection Manufacturing Base, Sales Area and Its Competitors
Table 92. Janssen Psychiatric Long-acting Injection Product Portfolios and Specifications
Table 93. Janssen Psychiatric Long-acting Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 94. Janssen Main Business
Table 95. Janssen Latest Developments
Table 96. Otsuka America Pharmaceutical, Inc. Basic Information, Psychiatric Long-acting Injection Manufacturing Base, Sales Area and Its Competitors
Table 97. Otsuka America Pharmaceutical, Inc. Psychiatric Long-acting Injection Product Portfolios and Specifications
Table 98. Otsuka America Pharmaceutical, Inc. Psychiatric Long-acting Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 99. Otsuka America Pharmaceutical, Inc. Main Business
Table 100. Otsuka America Pharmaceutical, Inc. Latest Developments
Table 101. Lundbeck Basic Information, Psychiatric Long-acting Injection Manufacturing Base, Sales Area and Its Competitors
Table 102. Lundbeck Psychiatric Long-acting Injection Product Portfolios and Specifications
Table 103. Lundbeck Psychiatric Long-acting Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 104. Lundbeck Main Business
Table 105. Lundbeck Latest Developments
Table 106. Eli Lilly Basic Information, Psychiatric Long-acting Injection Manufacturing Base, Sales Area and Its Competitors
Table 107. Eli Lilly Psychiatric Long-acting Injection Product Portfolios and Specifications
Table 108. Eli Lilly Psychiatric Long-acting Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 109. Eli Lilly Main Business
Table 110. Eli Lilly Latest Developments
Table 111. Alkermes Basic Information, Psychiatric Long-acting Injection Manufacturing Base, Sales Area and Its Competitors
Table 112. Alkermes Psychiatric Long-acting Injection Product Portfolios and Specifications
Table 113. Alkermes Psychiatric Long-acting Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 114. Alkermes Main Business
Table 115. Alkermes Latest Developments
Table 116. Par Pharmaceutical Basic Information, Psychiatric Long-acting Injection Manufacturing Base, Sales Area and Its Competitors
Table 117. Par Pharmaceutical Psychiatric Long-acting Injection Product Portfolios and Specifications
Table 118. Par Pharmaceutical Psychiatric Long-acting Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 119. Par Pharmaceutical Main Business
Table 120. Par Pharmaceutical Latest Developments
Table 121. AbbVie Basic Information, Psychiatric Long-acting Injection Manufacturing Base, Sales Area and Its Competitors
Table 122. AbbVie Psychiatric Long-acting Injection Product Portfolios and Specifications
Table 123. AbbVie Psychiatric Long-acting Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 124. AbbVie Main Business
Table 125. AbbVie Latest Developments
Table 126. Luye Pharmaceutical Basic Information, Psychiatric Long-acting Injection Manufacturing Base, Sales Area and Its Competitors
Table 127. Luye Pharmaceutical Psychiatric Long-acting Injection Product Portfolios and Specifications
Table 128. Luye Pharmaceutical Psychiatric Long-acting Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 129. Luye Pharmaceutical Main Business
Table 130. Luye Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of Psychiatric Long-acting Injection
Figure 2. Psychiatric Long-acting Injection Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Psychiatric Long-acting Injection Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Psychiatric Long-acting Injection Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Psychiatric Long-acting Injection Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Psychiatric Long-acting Injection Sales Market Share by Country/Region (2023)
Figure 10. Psychiatric Long-acting Injection Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Aripiprazole Long-acting Injection
Figure 12. Product Picture of Haloperidol Long-acting Injection
Figure 13. Product Picture of Paliperidone Long-acting Injection
Figure 14. Product Picture of Risperidone Long-acting Injection
Figure 15. Product Picture of Olanzapine Long-acting Injection
Figure 16. Product Picture of Others
Figure 17. Global Psychiatric Long-acting Injection Sales Market Share by Type in 2023
Figure 18. Global Psychiatric Long-acting Injection Revenue Market Share by Type (2019-2024)
Figure 19. Psychiatric Long-acting Injection Consumed in Schizophrenia
Figure 20. Global Psychiatric Long-acting Injection Market: Schizophrenia (2019-2024) & (K Units)
Figure 21. Psychiatric Long-acting Injection Consumed in Bipolar Disorder
Figure 22. Global Psychiatric Long-acting Injection Market: Bipolar Disorder (2019-2024) & (K Units)
Figure 23. Psychiatric Long-acting Injection Consumed in Others
Figure 24. Global Psychiatric Long-acting Injection Market: Others (2019-2024) & (K Units)
Figure 25. Global Psychiatric Long-acting Injection Sale Market Share by Application (2023)
Figure 26. Global Psychiatric Long-acting Injection Revenue Market Share by Application in 2023
Figure 27. Psychiatric Long-acting Injection Sales by Company in 2023 (K Units)
Figure 28. Global Psychiatric Long-acting Injection Sales Market Share by Company in 2023
Figure 29. Psychiatric Long-acting Injection Revenue by Company in 2023 ($ millions)
Figure 30. Global Psychiatric Long-acting Injection Revenue Market Share by Company in 2023
Figure 31. Global Psychiatric Long-acting Injection Sales Market Share by Geographic Region (2019-2024)
Figure 32. Global Psychiatric Long-acting Injection Revenue Market Share by Geographic Region in 2023
Figure 33. Americas Psychiatric Long-acting Injection Sales 2019-2024 (K Units)
Figure 34. Americas Psychiatric Long-acting Injection Revenue 2019-2024 ($ millions)
Figure 35. APAC Psychiatric Long-acting Injection Sales 2019-2024 (K Units)
Figure 36. APAC Psychiatric Long-acting Injection Revenue 2019-2024 ($ millions)
Figure 37. Europe Psychiatric Long-acting Injection Sales 2019-2024 (K Units)
Figure 38. Europe Psychiatric Long-acting Injection Revenue 2019-2024 ($ millions)
Figure 39. Middle East & Africa Psychiatric Long-acting Injection Sales 2019-2024 (K Units)
Figure 40. Middle East & Africa Psychiatric Long-acting Injection Revenue 2019-2024 ($ millions)
Figure 41. Americas Psychiatric Long-acting Injection Sales Market Share by Country in 2023
Figure 42. Americas Psychiatric Long-acting Injection Revenue Market Share by Country (2019-2024)
Figure 43. Americas Psychiatric Long-acting Injection Sales Market Share by Type (2019-2024)
Figure 44. Americas Psychiatric Long-acting Injection Sales Market Share by Application (2019-2024)
Figure 45. United States Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 46. Canada Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 47. Mexico Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 48. Brazil Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 49. APAC Psychiatric Long-acting Injection Sales Market Share by Region in 2023
Figure 50. APAC Psychiatric Long-acting Injection Revenue Market Share by Region (2019-2024)
Figure 51. APAC Psychiatric Long-acting Injection Sales Market Share by Type (2019-2024)
Figure 52. APAC Psychiatric Long-acting Injection Sales Market Share by Application (2019-2024)
Figure 53. China Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 54. Japan Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 55. South Korea Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 56. Southeast Asia Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 57. India Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 58. Australia Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 59. China Taiwan Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 60. Europe Psychiatric Long-acting Injection Sales Market Share by Country in 2023
Figure 61. Europe Psychiatric Long-acting Injection Revenue Market Share by Country (2019-2024)
Figure 62. Europe Psychiatric Long-acting Injection Sales Market Share by Type (2019-2024)
Figure 63. Europe Psychiatric Long-acting Injection Sales Market Share by Application (2019-2024)
Figure 64. Germany Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 65. France Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 66. UK Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 67. Italy Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 68. Russia Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 69. Middle East & Africa Psychiatric Long-acting Injection Sales Market Share by Country (2019-2024)
Figure 70. Middle East & Africa Psychiatric Long-acting Injection Sales Market Share by Type (2019-2024)
Figure 71. Middle East & Africa Psychiatric Long-acting Injection Sales Market Share by Application (2019-2024)
Figure 72. Egypt Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 73. South Africa Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 74. Israel Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 75. Turkey Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 76. GCC Countries Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Psychiatric Long-acting Injection in 2023
Figure 78. Manufacturing Process Analysis of Psychiatric Long-acting Injection
Figure 79. Industry Chain Structure of Psychiatric Long-acting Injection
Figure 80. Channels of Distribution
Figure 81. Global Psychiatric Long-acting Injection Sales Market Forecast by Region (2025-2030)
Figure 82. Global Psychiatric Long-acting Injection Revenue Market Share Forecast by Region (2025-2030)
Figure 83. Global Psychiatric Long-acting Injection Sales Market Share Forecast by Type (2025-2030)
Figure 84. Global Psychiatric Long-acting Injection Revenue Market Share Forecast by Type (2025-2030)
Figure 85. Global Psychiatric Long-acting Injection Sales Market Share Forecast by Application (2025-2030)
Figure 86. Global Psychiatric Long-acting Injection Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Psychiatric Long-acting Injection
Figure 2. Psychiatric Long-acting Injection Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Psychiatric Long-acting Injection Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Psychiatric Long-acting Injection Revenue Growth Rate 2019-2030 ($ millions)
Figure 8. Psychiatric Long-acting Injection Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9. Psychiatric Long-acting Injection Sales Market Share by Country/Region (2023)
Figure 10. Psychiatric Long-acting Injection Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture of Aripiprazole Long-acting Injection
Figure 12. Product Picture of Haloperidol Long-acting Injection
Figure 13. Product Picture of Paliperidone Long-acting Injection
Figure 14. Product Picture of Risperidone Long-acting Injection
Figure 15. Product Picture of Olanzapine Long-acting Injection
Figure 16. Product Picture of Others
Figure 17. Global Psychiatric Long-acting Injection Sales Market Share by Type in 2023
Figure 18. Global Psychiatric Long-acting Injection Revenue Market Share by Type (2019-2024)
Figure 19. Psychiatric Long-acting Injection Consumed in Schizophrenia
Figure 20. Global Psychiatric Long-acting Injection Market: Schizophrenia (2019-2024) & (K Units)
Figure 21. Psychiatric Long-acting Injection Consumed in Bipolar Disorder
Figure 22. Global Psychiatric Long-acting Injection Market: Bipolar Disorder (2019-2024) & (K Units)
Figure 23. Psychiatric Long-acting Injection Consumed in Others
Figure 24. Global Psychiatric Long-acting Injection Market: Others (2019-2024) & (K Units)
Figure 25. Global Psychiatric Long-acting Injection Sale Market Share by Application (2023)
Figure 26. Global Psychiatric Long-acting Injection Revenue Market Share by Application in 2023
Figure 27. Psychiatric Long-acting Injection Sales by Company in 2023 (K Units)
Figure 28. Global Psychiatric Long-acting Injection Sales Market Share by Company in 2023
Figure 29. Psychiatric Long-acting Injection Revenue by Company in 2023 ($ millions)
Figure 30. Global Psychiatric Long-acting Injection Revenue Market Share by Company in 2023
Figure 31. Global Psychiatric Long-acting Injection Sales Market Share by Geographic Region (2019-2024)
Figure 32. Global Psychiatric Long-acting Injection Revenue Market Share by Geographic Region in 2023
Figure 33. Americas Psychiatric Long-acting Injection Sales 2019-2024 (K Units)
Figure 34. Americas Psychiatric Long-acting Injection Revenue 2019-2024 ($ millions)
Figure 35. APAC Psychiatric Long-acting Injection Sales 2019-2024 (K Units)
Figure 36. APAC Psychiatric Long-acting Injection Revenue 2019-2024 ($ millions)
Figure 37. Europe Psychiatric Long-acting Injection Sales 2019-2024 (K Units)
Figure 38. Europe Psychiatric Long-acting Injection Revenue 2019-2024 ($ millions)
Figure 39. Middle East & Africa Psychiatric Long-acting Injection Sales 2019-2024 (K Units)
Figure 40. Middle East & Africa Psychiatric Long-acting Injection Revenue 2019-2024 ($ millions)
Figure 41. Americas Psychiatric Long-acting Injection Sales Market Share by Country in 2023
Figure 42. Americas Psychiatric Long-acting Injection Revenue Market Share by Country (2019-2024)
Figure 43. Americas Psychiatric Long-acting Injection Sales Market Share by Type (2019-2024)
Figure 44. Americas Psychiatric Long-acting Injection Sales Market Share by Application (2019-2024)
Figure 45. United States Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 46. Canada Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 47. Mexico Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 48. Brazil Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 49. APAC Psychiatric Long-acting Injection Sales Market Share by Region in 2023
Figure 50. APAC Psychiatric Long-acting Injection Revenue Market Share by Region (2019-2024)
Figure 51. APAC Psychiatric Long-acting Injection Sales Market Share by Type (2019-2024)
Figure 52. APAC Psychiatric Long-acting Injection Sales Market Share by Application (2019-2024)
Figure 53. China Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 54. Japan Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 55. South Korea Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 56. Southeast Asia Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 57. India Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 58. Australia Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 59. China Taiwan Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 60. Europe Psychiatric Long-acting Injection Sales Market Share by Country in 2023
Figure 61. Europe Psychiatric Long-acting Injection Revenue Market Share by Country (2019-2024)
Figure 62. Europe Psychiatric Long-acting Injection Sales Market Share by Type (2019-2024)
Figure 63. Europe Psychiatric Long-acting Injection Sales Market Share by Application (2019-2024)
Figure 64. Germany Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 65. France Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 66. UK Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 67. Italy Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 68. Russia Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 69. Middle East & Africa Psychiatric Long-acting Injection Sales Market Share by Country (2019-2024)
Figure 70. Middle East & Africa Psychiatric Long-acting Injection Sales Market Share by Type (2019-2024)
Figure 71. Middle East & Africa Psychiatric Long-acting Injection Sales Market Share by Application (2019-2024)
Figure 72. Egypt Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 73. South Africa Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 74. Israel Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 75. Turkey Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 76. GCC Countries Psychiatric Long-acting Injection Revenue Growth 2019-2024 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Psychiatric Long-acting Injection in 2023
Figure 78. Manufacturing Process Analysis of Psychiatric Long-acting Injection
Figure 79. Industry Chain Structure of Psychiatric Long-acting Injection
Figure 80. Channels of Distribution
Figure 81. Global Psychiatric Long-acting Injection Sales Market Forecast by Region (2025-2030)
Figure 82. Global Psychiatric Long-acting Injection Revenue Market Share Forecast by Region (2025-2030)
Figure 83. Global Psychiatric Long-acting Injection Sales Market Share Forecast by Type (2025-2030)
Figure 84. Global Psychiatric Long-acting Injection Revenue Market Share Forecast by Type (2025-2030)
Figure 85. Global Psychiatric Long-acting Injection Sales Market Share Forecast by Application (2025-2030)
Figure 86. Global Psychiatric Long-acting Injection Revenue Market Share Forecast by Application (2025-2030)
